Member Info for noix

Nelson
Have you a link please.

My previous reply (11.13am) was to imac1.
On a lighter note I'm getting 1.73725p to buy on HL and 1.74075 to sell !!!!

Precisely, this whole thread started because a poster said that he had his mortgage on this and two other shares and Older and wiser cautioned him on the pitfalls.

There was nothing subtle about my post, just pointing out the facts as I see them. Adding a touch of realism to the debate if you like.
To put things into context, the trial involves over 300 patients in 36 locations both here and in the USA. 4D do not collate the results this is done by the study team and when the findings are complete they will be forwarded to 4D Pharma for release to the market. Previous results from the Phase 1 and the interim analysis are freely available on the rns system.

Is clearly older and wiser than the team of rampers on here. Nothing is nailed on and results could be good, bad or indifferent, irrespective of what has been stated by the CEO. He's hardly going to promote failure and as it's a double blind, placebo controlled trial, he's as in the dark as the rest of us, until 4D get the results of course.
I wonder how many of the ramping crew have put their house on, in their words, "this dead cert".

Miggy
Although a lot of the information is way above our pay grades, there's a wealth of it on the excellent 4D website, detailing all aspects of the business, including the MicroRx platform, the library if you like.
This link gives the overview:
https://www.4dpharmaplc.com/en/developing-science/microrx
Then if you reaaly want to get into the detail I'd suggest having a read of the transcripts, together with the slides, of the excellent webinar presented last month:
https://www.4dpharmaplc.com/application/files/7715/9895/0010/4D_RD_webinar_Sep_2020_transcript.pdf
Page 3 of the transcript and the text for slide 9 is probably a good place to start and the text can be read, with cross reference to the slides themselves, at this link:
https://www.4dpharmaplc.com/application/files/5915/9894/9587/4D_RD_webinar_MicroRx_Sep_2020_final.pdf
For me there is a clear indicator that is constantly recurring in all of the therapies at various stages of development by 4D Pharma and that is anti-inflammatory. Inflammation is a key enemy of the human body and the Company are developing therapies which will lead in the fight against it in a range of illnesses, including cancers, respiratory diseases and neurodegenerative disorders.

Trek
I do indeed recall and I also recall your TA, although you haven't kept your promise to revisit at £1.77. I believe we peaked at £1.78 :) You must let me know sometime where I can pick up some tips on using TA (not at all my forte) and I believe I'm correct in saying that you use Market Screener and Trading View. I remember you posted a link to the latter which showed a couple of 5 step inserts. Did you calculate those or were they part of the Trading View package ?
Wondergoals
Seres certainly put the LBT sector back into the positive spotlight, which was quite ironic as they were the ones to reverse it previously with the failure of the Phase 2 trial of SER 109, as mentioned in the article linked below. Whether they or 4D are the absolute market leaders in LBT's is a debatable point. I believe our overall package is stronger but it could be argued that Seres are closer to market, although again, as the article explains, they may still have some work to do to get FDA approval. However, as you correctly point out, the market clearly viewed the news as a big positive, for them and the sector in general.
It's best to keep one's feet on the ground and people should not forget that the eagerly awaited Blautix trial results are Phase 2 and if good, I would imagine the next step will be some kind of partnership (not necessarily Merck) to take the process forward. They might well go for expediated clearance, such is the good safety profile. The Phase 1 Blautix results, although across a small patient group, showed 82% of participants with an overall improvement in symptoms vs 50% in the placebo group, results slightly better than those of Seres 109, with the previously mentioned caveats.
If this is replicated in the eagerly anticipated results, it will be good news.
Where we are clearly ahead of Seres is in the oncology space and particulary with our ground breaking MRx0518 Part A trial results in combination with the Merck drug Keytruda. Recruiting for Part B of the trial commenced in June and if the earlier results are replicated in the larger study of over 100 patients, all eyes really will be on 4D Pharma. We have been promised updates before the year end and we can also expect an update for the MRx0518 Imperial College trial for solid tumours, sooner rather than later.
Add to the list MRx4DP0004 for Asthma and CV19, together with the developing therapies for neuro degenerative disorders and as I suggested earlier, we have very much the industry leading portfolio, all enabled of course by the jewel in the crown, the MicroRx platform, which has so far spawned over 1000 granted patents, with a further 1000 in the pipeline.
And of course there's the mooted Nasdaq listing, which will serve to bring the above story to the full attention of the USA market, which is so much more attuned to the potential of ground breaking Pharma companies.
hTTps://www.nature.com/articles/d41573-020-00163-4

RichKen
We were singing from the same Hymn sheet until this part:
" Think £10 to £20, if they don't get caught out!"
Surely "caught out" isn't a typo for "bought out" if so I'll have some of what you are drinking :)

are in the probiotics sector of the microbiome. That's not the same space as 4D Pharma and its peers such as Seres.
Chalk and cheese bacteria.

We mustn't forget that, although not completely within the Company's control, there are 22 million warrants in large shareholders hands, including the directors, which will bring in a further £22 million when actioned.

Don't forget guys Wednesdays are usually 4d's best days.
ps How did I do :)

PT1
Apologies, I misread my notes. It is indeed the 25th September and believe that as it's a R&D webcast there is every chance LBT's and the microbiome could be discussed and the work collaboration that Marck have with 4D. There will obviously not be any market sensitive information but any PR is to be welcomed.

om
I'm tempted to say if you can't beat 'em join 'em but in the final analysis it's the way that you tell them and my way appears to have worked :)
tic

Just to give the rampers some ammunition and get them really excited :)
Historically Wednesdays are good days for 4D and sometimes very good.
Next Wednesday Merck are hosting a webcast and as has just been posted, Wednesday week is the last day of the 3rd quarter.
This does have a very strong consolidation feel about it now.

I don't do Mystic Meg but it could be a distant memory this afternoon.

Zengah
I admire your enthusiasm but too much of it can have a negative effect, which probably explains why the posts have been removed.
And perhaps you should ponder upon your statement "I see loads of my posts have been removed...well you won’t stop what’s happening".
Neither will your one liners influence what's happening, which should be further food for thought.

At the placing in February, 22 million warrants were issued, 1 warrant for every 2 shares subscribed to or issued to placees.
These warrants allowed the holders to subscribe for 1 ordinary share at a price of £1 up to the 5th anniversary of their admission date of 10th March 2020.
The blocklisting announcement issued this evening is a 6 monthly account that the Company has to release to the market to advise of the situation with the warrants. As shown, none have yet been issued and usually an individual rns would be released when they are. No names no pack drill but some people (and one in particular) continue to show their ignorance on many aspects of 4D and its operations and this has the inevitable negative effect on the board.

The UK is the Member State, so I'd say Italy and Ireland represent 18 patients and the USA a further 18 patients. This is presumably to reach the trial target of 90 patients but I wouldn't have thought it would have occured unless early results are positive. Although of seconday importance, these trials cost money, particularly when carried out abroad.

Just like to buses. One doesn't turn up for ages and then they all come at the same time.
Thanks to mad foetus who has just linked this:
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001597-30/GB
On the face of it, this is extending our trial into the Italy and Ireland. I'm taking the date as being the American style ie 4th September. The only surprise is that this hasn't been advised via an rns ..........yet :)

Thanks guys.
As we have come a long way down the line since the Spring, with many newcomers on board, I thought it an idea to re visit Duncan Peyton's first interview with Proative Investors. It gives some insight into the importance of the Asthma trial to the Company and their confidence in MRx0004. As a respiratory therapy this had to be put on hold due to the CV19 outbreak, but that in turn was the catalyst for our ongoing Covid trial. It's well worth hearing the whole presentation but the section from 7 mins 43 secs is particularly interesting as it underlines the confidence in the Asthma product but also understandably stresses how the Company's new exciting priority is oncology with MRx0158. And as we now know, those early "remarkable oncology results" have been confirmed in the recent rns and a sizeable extension to the trial (part B) is already enrolling both here and in the USA.
https://www.proactiveinvestors.co.uk/companies/news/920744/4d-pharma-plc-about-to-start-dosing-patients-in-its-phase-ii-trial-for-covid-19-920744.html